Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Radiopharm Theranostics Limited ( (AU:RAD) ) is now available.
Radiopharm Theranostics Limited announced the dosing of the first patient in its Phase 1 ‘HEAT’ clinical trial of RAD 202, a proprietary nanobody targeting HER2-positive expression in advanced solid tumors. This milestone marks a significant step in the company’s transition to a clinical-stage entity and aims to address the unmet need for HER2-positive metastatic patients who are progressing or unable to tolerate current treatment options, potentially improving clinical outcomes while preserving quality of life.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need. The company is listed on ASX and NASDAQ and has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules, and monoclonal antibodies for use in cancer treatment.
Average Trading Volume: 6,012,841
Technical Sentiment Signal: Hold
Current Market Cap: A$65.35M
See more insights into RAD stock on TipRanks’ Stock Analysis page.